Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready
Design Therapeutics Inc. is managing 9 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct art units, showing a significant range of technical classifications for the company's current filings. The portfolio involves 9 distinct examiners, which means that every pending action is currently assigned to a different individual at the patent office.
KOSAR, ANDREW D is the busiest examiner for the company, with 1 pending office action. This 1 action is part of the 9 total pending actions currently active. The distribution of 9 actions across 5 art units and 9 distinct examiners suggests a broad prosecution effort within the biotechnology and pharmaceuticals sector, with no concentration of matters under a single examiner. For practitioners, this means that each of the 9 pending office actions requires a unique strategy tailored to the specific examiner and art unit involved. The lack of examiner concentration across these 9 matters requires managing 9 separate relationships and prosecution styles simultaneously. This distribution across 5 art units highlights the scale and complexity of the company's current Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (22%) |
| §102 only | 1 (11%) |
| §112 only | 3 (33%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 1 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| KONOPKA, CATHERINE ANNE | 1 | 58.1% | +65.0% |
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
| SAEED, KAMAL A | 1 | 83.9% | +9.8% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18450775 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | SAEED, KAMAL A | — |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | — |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17759944 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | HAVLIN, ROBERT H | 71d |
| 18726567 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | KOSAR, ANDREW D | — |
| 18600510 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | KONOPKA, CATHERINE ANNE | — |
| 18590521 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | MEAH, MOHAMMAD Y | — |
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | — |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | — |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1626 | 2 |
| 1652 | 1 |
| 1627 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18726567 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | KOSAR, ANDREW D | — | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18600510 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | KONOPKA, CATHERINE ANNE | — | §102§103§112DPOther | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18590521 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18294494 | PROCESS FOR POLYAMIDE SYNTHESIS | PECKHAM, RICHARD GRANT | 1627 | §102§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18480353 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | SAMSELL, RILLA MARIE | 1624 | §102§112DP | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18450775 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | SAEED, KAMAL A | 1626 | §103 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 17759944 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | HAVLIN, ROBERT H | 1626 | §102 | Non-Final OA | 71d | Pending | Aug 10, 2023 |
| 18260549 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18256864 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial